ResMed
RMD
235.63
-1.25
-0.53%
ResMed
US · RMD
#644 by market cap
Listed 1970
235.63
-1.25
-0.53%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:01
Quant vs Street three independent views, side by side
StockVane factor grade
A
Momentum strategy signal
Hold
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Deteriorating
1 4
■ Upgrades■ Downgrades
- 1 upgrade vs 4 downgrades among tracked analyst rating changes.
- The single most recent change was actually an upgrade (RBC Capital moved from Hold to Buy on 2026-09-15), though the broader window skews toward downgrades.
Analyst consensus 8 analysts
Buy
Avg price target 274.29 +16.4%
Price target rangecurrent 235.63
Low235.00
Avg274.29
High320.00
Buy 50%
Hold 50%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-02 | BofA Securities | -- | Buy | 320.00 |
| 2026-11-02 | Citi | -- | Hold | 270.00 |
| 2026-10-30 | Mizuho Securities | -- | Buy | 270.00 |
| 2026-10-30 | Piper Sandler | -- | Hold | 260.00 |
| 2026-10-30 | KeyBanc | -- | Buy | 277.00 |
| 2026-10-30 | Needham | -- | Hold | -- |
| 2026-10-30 | Citi | -- | Hold | 270.00 |
| 2026-10-30 | RBC Capital | -- | Buy | 288.00 |
| 2026-10-13 | Mizuho Securities | -- | Buy | 240.00 |
| 2026-10-13 | BofA Securities | -- | Buy | 320.00 |
| 2026-10-02 | Stifel | -- | Hold | 235.00 |
| 2026-09-25 | Stifel | -- | Hold | -- |
| 2026-09-15 | RBC Capital | -- | Buy | 262.00 |
| 2026-09-10 | Citi | -- | Hold | 240.00 |
| 2026-08-31 | KeyBanc | -- | Buy | 267.00 |
| 2026-08-19 | Rothschild & Co Redburn | -- | Hold | 230.00 |
| 2026-08-11 | Mizuho Securities | -- | Buy | 235.00 |
| 2026-08-07 | William Blair | -- | Buy | -- |
| 2026-08-07 | Piper Sandler | -- | Hold | 225.00 |
| 2026-08-07 | KeyBanc | -- | Buy | 255.00 |
| 2026-08-07 | Needham | -- | Hold | -- |
| 2026-08-07 | RBC Capital | -- | Hold | 244.00 |
| 2026-08-04 | Needham | -- | Hold | -- |
| 2026-07-29 | BofA Securities | -- | Buy | 320.00 |
| 2026-07-20 | William Blair | -- | Buy | -- |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-09-15 | RBC Capital | Hold → Buy | 262.00 |
| 2026-07-16 | RBC Capital | Buy → Hold | 234.00 |
| 2026-07-10 | Citi | Buy → Hold | 235.00 |
| 2026-06-17 | Morgan Stanley | Buy → Hold | 230.00 |
| 2025-12-16 | Baird | Buy → Hold | 275.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2027/Q1 | 2026-10-29 | After close | ±7.24% | -9.05% (beat) |
| 2026/Q4 | 2026-08-06 | After close | ±7.75% | -5.06% (in line) |
| 2026/Q3 | 2026-04-30 | After close | ±7.98% | -4.11% (in line) |
| 2026/Q2 | 2026-01-29 | After close | ±7.12% | +0.27% (in line) |
| 2026/Q1 | 2025-10-30 | After close | ±10.09% | -2.13% (in line) |
| 2025/Q4 | 2025-07-31 | After close | ±9.48% | +2.67% (in line) |
| 2025/Q3 | 2025-04-23 | After close | ±10.51% | +10.10% (in line) |
| 2025/Q2 | 2025-01-30 | After close | ±9.29% | -8.33% (in line) |
| 2025/Q1 | 2024-10-24 | After close | ±11.07% | +7.12% (in line) |
| 2024/Q4 | 2024-08-01 | After close | ±13.29% | +4.23% (in line) |
| 2024/Q2 | 2024-01-24 | After close | ±8.85% | +8.48% (in line) |
| 2024/Q1 | 2023-10-26 | After close | ±12.25% | -2.94% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 20:01:25 · For reference only, not investment advice and not tailored to your situation.
ResMed discussion 0 comments